Go Pro
NASDAQ:COCH

Envoy Medical Q4 2025 Earnings Report

Envoy Medical logo
$0.76 +0.07 (+9.41%)
As of 10:29 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Envoy Medical EPS Results

Actual EPS
-$0.26
Consensus EPS
-$0.24
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

Envoy Medical Revenue Results

Actual Revenue
$0.08 million
Expected Revenue
$0.03 million
Beat/Miss
Beat by +$45.00 thousand
YoY Revenue Growth
N/A

Envoy Medical Announcement Details

Quarter
Q4 2025
Time
Before Market Opens
Conference Call Date
Monday, March 23, 2026
Conference Call Time
8:00AM ET

Upcoming Earnings

Envoy Medical's Q2 2026 earnings is estimated for Thursday, July 30, 2026, based on past reporting schedules

Earnings Documents

Envoy Medical Earnings Headlines

Man who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”
In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon adviser Jim Rickards publicly predicted a Trump victory before election night. Now Rickards is issuing a new forecast he calls a potential mid-term meltdown, one he believes could send shockwaves through financial markets.tc pixel
Envoy Medical Inc - Ordinary Shares - Class A
See More Envoy Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Envoy Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Envoy Medical and other key companies, straight to your email.

About Envoy Medical

Envoy Medical (NASDAQ:COCH) (NASDAQ:COCH) is a medical device company focused on non-invasive neuromodulation therapies for dysphagia, a swallowing disorder that affects patients following neurological events or due to degenerative conditions. The company’s lead technology delivers targeted electrical stimulation designed to strengthen the muscles and neural pathways involved in the swallowing process.

Envoy Medical’s flagship therapy has received regulatory clearance from the U.S. Food and Drug Administration and is being introduced through rehabilitation centers, speech-language pathology clinics and acute care hospitals. The company works closely with healthcare providers to integrate its device into patient care pathways, supporting therapy both in clinical environments and at home.

Headquartered in the Minneapolis–Saint Paul metropolitan area, Envoy Medical currently serves the U.S. market and is evaluating opportunities for expansion into select international regions. Its leadership team combines expertise in medical device development, rehabilitation sciences and commercial operations, backed by private financing aimed at advancing innovative therapies for neurological and musculoskeletal disorders.

View Envoy Medical Profile